证券代码：688799 证券简称：华纳药厂 公告编号：2025-057 （一）审议通过《关于部分募集资金投资项目子项目调整及延期的方案的 议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 湖南华纳大药厂股份有限公司 第四届董事会第六次临时会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届董事会第六次临 时会议于 2025 年 6 月 11 日以现场结合通讯方式召开，本次会议的通知于 2025 年 6 月 6 日送达公司全体董事。会议由董事长黄本东先生主持，应出席董事 7 人，实际出席董事 7 人。会议的召集、召开、表决程序符合相关法律、法规及《湖 南华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作 决议合法有效。 二、董事会会议审议情况 本次会议审议通过了如下议案： 本议案已经第四届董事会战略委员会第四次临时会议审议通过。 表决结果：7 票同意，0 票反对，0 票弃 ...

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

湖南华纳大药厂股份有限公司 股票交易异常波动公告 证券代码：688799 证券简称：华纳药厂 公告编号：2025-056 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南华纳大药厂股份有限公司（以下简称"公司"）股票交易连续 3 个交 易日内（2025 年 5 月 28 日、2025 年 5 月 29 日、2025 年 5 月 30 日）收盘价格 涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所 科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查并向控股股东、实际控制人书面发函查证，截至 2025 年 5 月 30 日，确认不存在应披露而未披露的重大事项或重要信息。 公司特别提醒广大投资者，理性决策，注意防范投资风险。 一、股票交易异常波动的具体情况 公司股票交易连续 3 个交易日内（2025 年 5 月 28 日、2025 年 5 月 29 日、 2025 年 5 月 30 日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所 交易规则 ...

致:湖南华纳大药厂股份有限公司 《关于湖南华纳大药厂股份有限公司股票交易异常波动的 询证函》的回函 截至本回函出具日,作为湖南华纳大药厂股份有限公司(以下简称"公司") 控股股东、实际控制人,不存在涉及公司的应披露而未披露的重大事项,包括 但不限于并购重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 在公司本次股票交易异常波动期间,作为公司控股股东、实际控制人,不 存在买卖公司股票的情形。 控股股东:湖南华纳医药投资合 (有限合伙) 黄本东 贵公司《关于湖南华纳大股份有限公司股票交易异常波动的询证函》已收 悉,现就公司问询事项回复如下: 日期: 2025年 5 月 30 日 特此回复。 ...

华纳药厂发布异动公告，经公司自查，公司目前日常经营情况正常。市场环境、行业政策未发生重大调 整，公司生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。截至本公告披露日，在创新 药研发领域，公司在研的中药1类创新药干清颗粒已顺利完成Ⅱ期临床试验，Ⅲ期临床试验相关筹备工 作全面启动；以子公司上海致根医药科技有限公司为项目平台开展的ZG系列产品中，ZG-1正在开展Ⅱa 期临床试验，预计今年完成Ⅱa临床试验，并将根据临床试验进展情况开展Ⅱb期临床试验；ZG-2项目 正在开展Ⅰ期临床试验，预计今年完成I期临床试验，并将根据临床试验进展情况开展Ⅱ期临床试验； 以子公司湖南省天玑珍稀中药材发展有限公司为项目平台展开的濒危动物药材替代品研发项目，在相关 审评审批政策指南清晰的背景下，各个项目的研究工作稳步推进，其中的ZY022项目预计今年完成IND 申请，进入I期临床试验阶段。 ...

Market Overview - On May 30, the last trading day before the Dragon Boat Festival, the market opened lower and experienced weak fluctuations, with the North Stock 50 index rising by 0.25% while the Shanghai Composite Index fell by 0.31% to 3353.07 points [1] - The total trading volume of A-shares for the half day was 771.57 billion yuan [1] Monetary Policy - The People's Bank of China announced a 7-day reverse repurchase operation of 291.1 billion yuan at a fixed rate of 1.40%, with a net injection of 148.6 billion yuan for the day [1] Industry Developments - The China Securities Association is formulating a special evaluation method for securities companies, focusing on contributions to key areas such as technology finance, green finance, and digital finance [1] Pharmaceutical Sector Performance - The pharmaceutical sector saw significant gains, with stocks like Ruizhi Pharmaceutical and Huana Pharmaceutical hitting a 20% limit up, while other related sectors such as CRO and brain-computer interface also experienced upward trends [2] Sector Performance Data - The top performing sectors included: - Chicken: +2.55% - Innovative Drugs: +2.52% - Pork: +2.47% - Immune Therapy: +1.94% - COVID-19 Drug Concept: +1.94% [3] Investment Outlook for Innovative Drugs - The investment value of innovative drugs is viewed positively due to ongoing supportive policies, improving payment conditions, and upgrading research capabilities of supply-side enterprises [4] - Companies with strong innovation capabilities and rich product pipelines are expected to benefit in the long term from the continuous promotion of bulk purchasing of drugs and consumables [4] Company Profiles - **Huana Pharmaceutical**: A high-tech enterprise focused on the R&D, production, and sales of chemical drugs and traditional Chinese medicine, with a promising antidepressant drug ZG001 [7] - **Kexing Pharmaceutical**: An innovative biopharmaceutical company engaged in the R&D and sales of recombinant protein drugs and micro-ecological preparations, with a strong international presence [7] - **Guanhao Biological**: Actively advancing the application for a human genetic resource sample library to support innovation in drug development and health services [7] - **Haichuang Pharmaceutical**: An international innovative drug company focusing on cancer and metabolic diseases, utilizing PROTAC technology for drug development [8]

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

Group 1 - The Shanghai Stock Exchange Science and Technology Innovation Board Composite Index (000680) has seen a strong increase of 2.06%, with notable gains from component stocks such as GeLun Electronics (688206) up 20.01%, YiFang Bio (688382) up 20.00%, and JingJin Electric (688280) up 14.96% [3] - The Huaxia Science and Technology Innovation Index ETF (589000) rose by 1.97%, with a latest price of 0.93 yuan, and recorded a turnover rate of 3.41% during the trading session, with a transaction volume of 92.32 million yuan [3] - Over the past month, the average daily transaction volume of the Huaxia Science and Technology Innovation Index ETF reached 142 million yuan, ranking first among comparable funds [3] Group 2 - The recent China-Europe semiconductor upstream and downstream enterprise symposium emphasized the importance of leveraging complementary advantages and deepening trade cooperation while opposing unilateralism and bullying, aiming to maintain global semiconductor supply chain security and stability [3] - The Ministry of Commerce's emphasis on rare earth export control policies during the symposium may indicate a potential relaxation of export controls on rare earths for European chip companies [3] - Shanxi Securities noted that the tightening of chip export restrictions combined with the performance improvements of domestic chips will sustain high demand for AI computing power from downstream internet and intelligent computing centers [4] Group 3 - The focus is on first-tier manufacturers with significant performance improvements in new generation products on the chip side, and on the server side, the expected growth of H20 is anticipated to boost the performance of traditional server leaders [4] - The Huaxia Science and Technology Innovation Index ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Composite Index, focusing on hard technology sectors, particularly in new generation information technology, high-end equipment, biomedicine, new energy, new materials, and energy conservation and environmental protection [4]